Key positives are a scientifically compelling lead candidate engineered to address known problems in a hot immuno-oncology target, an exclusive license that could limit direct competition on that specific molecule, a simple asset base with minimal long-term commitments, and demonstrated ability to raise capital despite early-stage risks. The company’s focus on combination strategies with existing checkpoint inhibitors is also strategically aligned with current treatment paradigms.

Major risks include the absence of revenue, substantial ongoing losses, and very weak liquidity, all of which raise questions about near-term solvency without additional funding. The balance sheet shows negative equity and heavy reliance on short-term obligations. On the strategic side, the pipeline appears concentrated in a single core asset after reported loss of other programs, and the targeted CD47 space is both crowded and technically challenging. Regulatory, clinical, financing, and listing-compliance risks all sit at elevated levels.

Looking ahead, the company’s trajectory hinges on two pillars: securing enough capital to remain a going concern and successfully moving IBA101 into and through early clinical trials. If the molecule delivers on its promise and the company can stabilize its finances, Liminatus could carve out a meaningful position in CD47-based oncology. If funding remains constrained or clinical results disappoint, the current financial stress and narrow pipeline leave little cushion. Overall, the outlook is highly binary and strongly dependent on execution and external financing conditions.